Porton Delivers Strong 2022 Performance With 127% Sales Growth
In 2022, Porton delivers RMB 7 billion revenue and 127% revenue growth. Net profit attributable...
Porton Achieves Above-Average S&P Global ESG Score
Porton Pharma Solutions Ltd. is proud to announce that it has made the top quartile...
Porton Pharma Solutions Honored as Top CDMO by Roche Group
Porton’s recognition by Roche is a testament to the high-quality service and...
Join Us at the AAPS Annual Meeting in Boston, October 16-19, 2023
J-STAR Research and Porton Pharma Solutions Ltd. are excited to be exhibiting at this year’s American Association of...
Porton Reports Strong Interim Results 2022
The year 2022 is an important milestone for Porton. Despite of the...
Porton Pharma Solutions Ltd. to Expand Operations in Europe
PORTON PHARMA SOLUTIONS LTD., a world leading CDMO (Hereafter PORTON) announces plans to invest into...
Porton Pharma Solutions Ltd. To Expand Operations In Europe
PORTON PHARMA SOLUTIONS LTD., a world leading CDMO (Hereafter PORTON) announces plans...
New State-of-the-Art Crystallization and Drug Product Facility
Porton is excited to announce construction of a new, state-of-the-art Crystallization and Drug Product facility...
Explore the 2022 Pharma Crystallization Summit Technical Program
We are very excited to announce the technical program of Pharma Crystallization Summit 2022. This...